ABVC Capital Lease Obligations from 2010 to 2025
| ABVC Stock | USD 0.86 0.06 7.50% |
Capital Lease Obligations | First Reported 2019-03-31 | Previous Quarter 607 K | Current Value 507.7 K | Quarterly Volatility 494.9 K |
Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 3 M, Selling General Administrative of 5 M or Total Revenue of 157.4 K, as well as many indicators such as Price To Sales Ratio of 36.05, Dividend Yield of 0.0 or PTB Ratio of 0.66. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
ABVC | Capital Lease Obligations |
Latest ABVC Biopharma's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of ABVC Biopharma over the last few years. ABVC Biopharma capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to ABVC Biopharma asset purchases. For example, ABVC Biopharma can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as ABVC Biopharma control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. ABVC Biopharma's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ABVC Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
ABVC Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 766,390 | |
| Geometric Mean | 701,694 | |
| Coefficient Of Variation | 50.05 | |
| Mean Deviation | 287,987 | |
| Median | 539,803 | |
| Standard Deviation | 383,568 | |
| Sample Variance | 147.1B | |
| Range | 1.2M | |
| R-Value | 0.54 | |
| Mean Square Error | 112.2B | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | 43,252 | |
| Total Sum of Squares | 2.2T |
ABVC Capital Lease Obligations History
About ABVC Biopharma Financial Statements
ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 728.4 K | 920.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of ABVC Biopharma Correlation against competitors. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 23.507 | Return On Assets | Return On Equity |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.